 My name is Ambrose Agweyu. I'm a pediatrician and an epidemiologist. I work here at the Chemery Welcome Trust Research Program as a clinical research fellow with the Health Services Unit. I joined the Chemery Welcome Trust Program in 2009, where I was developing an emerging area of work around childhood pneumonia. Since then I've been involved in clinical trials, observational studies and systematic reviews to inform guideline development for the care of children with pneumonia in hospitals. My research can help us fight tropical illnesses because pneumonia is the leading infectious cause of death among children aged under five. Almost 900,000 children die every year due to pneumonia and most of these deaths occur in low and middle income countries. So the research which I'm involved in which aims at understanding the effectiveness of currently recommended treatments and looking for new alternative treatments for pneumonia is particularly important in fighting tropical illnesses. The current work which we're working on is funded by the DFID NIHR MRC and Welcome Trust Joint Global Health Trial Scheme. It's a large study that is taking place in 12 sites recruiting over 4,000 children to investigate alternative treatment, antibiotic treatment for pneumonia in hospitalized children and also looking at approaches to giving supportive care for these children with pneumonia. While there are new drugs that are being developed, I think it's important to also consider research around approaches to preserving the currently existing treatments. So I think work around vaccines, work around antimicrobial resistance and understanding ways in which we can reduce resistance to currently available treatment is particularly important now. I also think that research in health systems is also an emerging area of importance. All these new treatments which we develop will eventually be delivered in hospitals with various levels of resources and health systems research aims at optimizing the delivery of these interventions within contexts which might not be optimal necessarily. My line of research is important because infectious diseases remain a leading cause of illness and death in children. The work which I'm involved in is, we refer to it as pragmatic in that it aims at generating evidence that is applicable in real world settings. In settings where you might have health worker shortages which is common in our hospitals, in settings where treatments might not necessarily be delivered in the ideal way. So I think the work which I'm involved in working with hospitals and doing research with practicing clinicians provides a unique type of evidence which is applicable in real world settings. My research fits in with translational medicine because we work very closely with hospitals where care is delivered. I'm also part of technical panels in the Ministry of Health where we've been sharing our findings and working with them on how to translate that evidence into policy. A good example is research which we conducted in 2011 to 2013 that was discussed by a guideline panel convened by the Ministry of Health in 2014 and eventually contributed to a major guideline revision for the care of children with pneumonia. I also sit on a technical panel with the WHO and recently they convened a meeting where they specifically discussed some of the evidence which we had generated and it's relevant to a possible change in the global guidance for treating children who present with signs of pneumonia in hospitals.